SCHEMBL4158077

SCHEMBL4158077

Cc1ccnc2[nH]c(-c3ccoc3)nc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMIGD3 P0DMS9 2/20 0.42
ADORA1 P30542 2/20 0.42
PDE10A Q9Y233 2/20 0.39
MAPT P10636 2/20 0.37
MGAM O43451 2/20 0.37
GAA P10253 2/20 0.37
SI P14410 2/20 0.37
MGAM2 Q2M2H8 2/20 0.37
MEN1 O00255 3/20 0.35
CYP1A2 P05177 3/20 0.35
CYP3A4 P08684 3/20 0.35
KMT2A Q03164 3/20 0.35
USP2 O75604 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP2D6 P10635 2/20 0.35
HSD17B10 Q99714 2/20 0.35
TP53 P04637 1/20 0.35
ALOX15 P16050 1/20 0.35
SCD O00767 1/20 0.34
CCR1 P32246 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665479 0.80 TNKS (0.51) MAPTMGAMGAASIMGAM2
SCHEMBL8237142 0.79 GSK3B (0.41) TMIGD3ADORA1MAPTSCDAURKA
SCHEMBL4167033 0.77 GSK3B (0.42) TMIGD3ADORA1GSK3B
SCHEMBL4144871 0.77 PKN1 (0.47) TMIGD3ADORA1GAAALDH1A1HPGD
SCHEMBL17236527 0.77 TNKS (0.52) MAPTMGAMGAASIMGAM2
SCHEMBL4148211 0.77 MGAM (0.57) MGAMGAASIMGAM2ALDH1A1
SCHEMBL4157363 0.77 MGAM (0.57) MGAMGAASIMGAM2CYP1A2
SCHEMBL17224938 0.77 TNKS (0.49) MGAMGAASIMGAM2
SCHEMBL4153600 0.75 CLK2 (0.43) MGAMGAASIMGAM2TDO2
SCHEMBL21101968 0.75 PARP1 (0.54) ALDH1A1ALOX15AURKASMN1; SMN2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP disclosed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 TMIGD3 2151/4885ADORA1 3514/4885PDE10A 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.